Ascelia Pharma AB (OSTO:ACE) Other Financing: kr-3.81 Mil (TTM As of Mar. 2026)


OSTO:ACE Ascelia Pharma AB OSTO:ACE
29 GF Score
Price kr2.96
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Other Financing?

Ascelia Pharma AB OSTO:ACE +1.02% 29 Other Financing is kr-3.81 Mil as of Mar. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Ascelia Pharma AB's Other Financing for the three months ended in Mar. 2026 was kr0.00 Mil.

Ascelia Pharma AB's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was kr-3.81 Mil.

Ascelia Pharma AB Other Financing Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB Other Financing Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only -13.27 -0.08 -0.03 -15.21 -3.81

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -1.32 -2.30 -0.19 0.00
OSTO:ACE
29GF Score
Ascelia Pharma AB OSTO:ACE
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-3.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of kr-3.81 Mil mean?
Ascelia Pharma AB (OSTO:ACE) has a Other Financing of kr-3.81 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Ascelia Pharma AB and its competitors.
Is Ascelia Pharma AB's Other Financing too high?
Ascelia Pharma AB's current Other Financing is kr-3.81 Mil. Overall, Ascelia Pharma AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Other Financing compare to VRTX and REGN?
Ascelia Pharma AB's Other Financing of kr-3.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current Other Financing is kr-3.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current Other Financing of kr-3.81 Mil. The current Other Financing is kr-3.81 Mil. Ascelia Pharma AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current Other Financing is kr-3.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
29GF Score

Get the complete analysis for OSTO:ACE

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.96
Price